

# **2018 Ischemia-Reperfusion Injury Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Ischemia-Reperfusion Injury Market**

<https://marketpublishers.com/r/21721320104EN.html>

Date: June 2018

Pages: 70

Price: US\$ 999.00 (Single User License)

ID: 21721320104EN

## **Abstracts**

Cardiac ischemia-reperfusion injury (IRI) is a heart related condition in which blood supply is restored to the tissue after some period of ischemia or absence of oxygen supply. The new supply causes additional complications such as inflammation, innate immunity, and oxidative stress instead of restoring regular function.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Ischemia-Reperfusion Injury pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Ischemia-Reperfusion Injury pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Ischemia-Reperfusion Injury pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

## Contents

### 1 TABLE OF CONTENTS

#### 1.1 List of LIST OF FIGURES

#### 1.2 List of Tables

### 2 ISCHEMIA-REPERFUSION INJURY PIPELINE ANALYSIS

#### 2.1 Disease and Pipeline Overview

#### 2.2 Ischemia-Reperfusion Injury Pipeline Snapshot

#### 2.3 Ischemia-Reperfusion Injury Pipeline by Phase

#### 2.4 Ischemia-Reperfusion Injury Pipeline by Company

#### 2.5 Ischemia-Reperfusion Injury Pipeline by Mechanism of Action

### 3 ISCHEMIA-REPERFUSION INJURY- COMPANY WISE PIPELINE ANALYSIS

Angion Biomedica Corp

Armaron Bio Pty Ltd

BioMedCore Inc

Bolder Biotechnology Inc

Catalyst Biosciences Inc

Celdara Medical LLC

CFM Pharma Holding BV

Corline Biomedical AB

Faraday Pharmaceuticals

Glucox Biotech AB

Ischemix Inc

Mallinckrodt Plc

Miragen Therapeutics Inc

NovelMed Therapeutics Inc

Opsona Therapeutics Ltd

Pharming Group NV

Prolong Pharmaceuticals LLC

Prothix BV

Radikal Therapeutics Inc

SBI Pharmaceuticals Co Ltd

TheraSource LLC

TRIM-edicine Inc

X-In8 Biologicals Corp

List Continues....

#### **4 ISCHEMIA-REPERFUSION INJURY R&D PIPELINE SNAPSHOTS**

Drug wise Pipeline Details

Therapeutic Candidate Name

Originator

Co-Developer/ License Partner

Orphan Drug Designation

Development Phase

Mechanism of Action

Current Status

Ongoing Clinical Trial Details

#### **5 RECENT DEVELOPMENTS IN ISCHEMIA-REPERFUSION INJURY PIPELINE**

#### **6 APPENDIX**

6.1 About VPA Research

6.2 Sources and Research Methodology

## List Of Figures

### LIST OF FIGURES

Figure 1: Ischemia-Reperfusion Injury Pipeline by Phase, H2- 2018

Figure 2: Ischemia-Reperfusion Injury Pipeline by Companies, H2- 2018

Figure 3: Company Wise Pipeline Drug Phases, H2- 2018

Figure 4: Ischemia-Reperfusion Injury Pipeline by Mechanism of Action, H2- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

## List Of Tables

### LIST OF TABLES

Ischemia-Reperfusion Injury Pipeline by Phase, H2- 2018

Ischemia-Reperfusion Injury Pipeline by Companies, H2- 2018

Ischemia-Reperfusion Injury Pipeline by Mechanism of Action, H2- 2018

Table 1: Angion Biomedica Corp Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 2: Armaron Bio Pty Ltd Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 3: BioMedCore Inc Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 4: Bolder Biotechnology Inc Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 5: Catalyst Biosciences Inc Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 6: Celdara Medical LLC Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 7: CFM Pharma Holding BV Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 8: Corline Biomedical AB Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 9: Faraday Pharmaceuticals Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 10: Glucox Biotech AB Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 11: Ischemix Inc Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 12: Mallinckrodt Plc Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 13: Miragen Therapeutics Inc Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 14: NovelMed Therapeutics Inc Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 15: Opona Therapeutics Ltd Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 16: Pharming Group NV Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 17: Prolong Pharmaceuticals LLC Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 18: Prothix BV Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 19: Radikal Therapeutics Inc Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 20: SBI Pharmaceuticals Co Ltd Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 21: TheraSource LLC Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 22: TRIM-edicine Inc Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 23: X-In8 Biologicals Corp Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

Table 24: List Continues.... Ischemia-Reperfusion Injury Pipeline Drugs, H2- 2018

## I would like to order

Product name: 2018 Ischemia-Reperfusion Injury Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Ischemia-Reperfusion Injury Market

Product link: <https://marketpublishers.com/r/21721320104EN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/21721320104EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970